The Japan Times - Study shows how fast kilos return after ending weight-loss drugs

EUR -
AED 4.241501
AFN 76.225899
ALL 93.554047
AMD 421.168408
AOA 1060.230438
ARS 1715.656895
AUD 1.639343
AWG 2.078882
AZN 1.960998
BAM 1.957978
BBD 2.319179
BDT 142.188136
BHD 0.434183
BIF 3417.00026
BMD 1.154934
BND 1.477844
BOB 13.673207
BRL 5.867647
BSD 1.151481
BTN 109.772084
BWP 15.700461
BYN 3.349625
BYR 22636.715706
BZD 2.315876
CAD 1.618352
CDF 2627.475914
CHF 0.931576
CLF 0.027214
CLP 1074.552598
CNY 7.797307
CNH 7.795773
COP 3581.683414
CRC 522.981641
CUC 1.154934
CUP 30.605764
CVE 110.387769
CZK 24.225868
DJF 205.048047
DKK 7.475152
DOP 66.804297
DZD 153.472687
EGP 58.835639
ERN 17.324017
ETB 184.006946
FJD 2.556967
FKP 0.856809
GBP 0.855893
GEL 3.020138
GGP 0.856809
GHS 13.460971
GIP 0.856809
GMD 84.891799
GNF 10108.242008
GTQ 8.785771
GYD 240.867884
HKD 9.057285
HNL 30.853314
HRK 7.54669
HTG 150.557444
HUF 363.867906
IDR 20822.313646
ILS 3.537506
IMP 0.856809
INR 110.16978
IQD 1508.477672
IRR 1588179.269833
ISK 142.219015
JEP 0.856809
JMD 182.292739
JOD 0.818845
JPY 181.57706
KES 148.945652
KGS 100.999312
KHR 4659.181767
KMF 493.156852
KRW 1666.524381
KWD 0.357037
KYD 0.959567
KZT 545.626826
LAK 26077.001864
LBP 103117.983955
LKR 386.549906
LRD 207.841153
LSL 19.045882
LTL 3.410221
LVL 0.698608
LYD 7.367194
MAD 10.756663
MDL 20.122379
MGA 4924.476818
MKD 61.593502
MMK 2424.850425
MNT 4151.45627
MOP 9.302246
MRU 46.277468
MUR 54.282161
MVR 17.855218
MWK 1996.620567
MXN 20.037155
MYR 4.71814
MZN 73.811907
NAD 19.045882
NGN 1575.746553
NIO 42.37713
NOK 11.066871
NPR 175.635335
NZD 1.957192
OMR 0.444134
PAB 1.151481
PEN 3.90234
PGK 5.155734
PHP 70.745488
PKR 319.79146
PLN 4.307178
PYG 6865.635703
QAR 4.209281
RON 5.253334
RSD 117.520702
RUB 91.505504
RWF 1690.379977
SAR 4.325144
SBD 9.333147
SCR 15.60035
SDG 692.961179
SEK 11.020558
SGD 1.479777
SLE 28.523045
SOS 658.031838
SRD 43.635158
STD 23904.811825
STN 24.527278
SVC 10.075205
SZL 19.043179
THB 38.719182
TJS 10.62802
TMT 4.05382
TND 3.385065
TRY 54.854577
TTD 7.818696
TWD 37.31489
TZS 3050.792978
UAH 51.393558
UGX 4323.808778
USD 1.154934
UYU 46.331528
UZS 13783.329302
VES 861.230481
VND 30375.354155
VUV 137.078995
WST 3.158158
XAF 656.687343
XAG 0.020053
XAU 0.000285
XCD 3.121268
XCG 2.075208
XDR 0.816708
XOF 656.687343
XPF 119.331742
YER 275.221161
ZAR 19.011665
ZMK 10395.793255
ZMW 21.630056
ZWL 371.88843
  • CMSD

    0.0900

    22.11

    +0.41%

  • CMSC

    0.0300

    21.84

    +0.14%

  • BCE

    -0.0200

    21.68

    -0.09%

  • RYCEF

    -0.3100

    19.55

    -1.59%

  • GSK

    -0.3800

    51.69

    -0.74%

  • BCC

    1.0000

    76.38

    +1.31%

  • NGG

    -0.4200

    79.97

    -0.53%

  • RIO

    -0.3300

    96.85

    -0.34%

  • RBGPF

    0.0000

    69.21

    0%

  • AZN

    -1.7000

    169.64

    -1%

  • BTI

    -1.0400

    60.65

    -1.71%

  • JRI

    0.0900

    12.96

    +0.69%

  • VOD

    -0.3600

    15.78

    -2.28%

  • RELX

    -1.1900

    35.42

    -3.36%

  • BP

    1.0000

    45.22

    +2.21%

Study shows how fast kilos return after ending weight-loss drugs
Study shows how fast kilos return after ending weight-loss drugs / Photo: Armend NIMANI - AFP/File

Study shows how fast kilos return after ending weight-loss drugs

When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.

Text size:

But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.

A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.

They have been found to help people lose between 15-20 percent of their body weight.

"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.

However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.

This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.

So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.

Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.

While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.

However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.

The researchers projected that the participants would return to their original weight in 18 months.

Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.

People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.

This meant that people taking the drugs regained their weight four times faster.

- 'Starting point, not a cure' -

"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.

But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.

This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.

Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."

"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.

If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.

"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.

"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.

K.Nakajima--JT